Quinuclidines PRIMA-1 and its analog APR-246 (phase I and phase II clinical trials) have demonstrated their ability to inhibit cell proliferation and increase apoptosis in cancer cell lines and other models, although it has been reported that they could display non-p53 related activity [165]. This evidence concerns the gene TP53 and cancer.